[Modification of the level of serum neurophysin during chronic renal failure]. 1972

J J Legros, and D Moray, and A Fassotte, and P Franchimont

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D009481 Neurophysins Carrier proteins for OXYTOCIN and VASOPRESSIN. They are polypeptides of about 10-kDa, synthesized in the HYPOTHALAMUS. Neurophysin I is associated with oxytocin and neurophysin II is associated with vasopressin in their respective precursors and during transportation down the axons to the neurohypophysis (PITUITARY GLAND, POSTERIOR). Neurophysin,Neurophysin I,Neurophysin II,Neurophysin III,Oxytocin-Associated Neurophysin,Vasopressin-Associated Neurophysin,Neurophysin, Oxytocin-Associated,Neurophysin, Vasopressin-Associated,Oxytocin Associated Neurophysin,Vasopressin Associated Neurophysin
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012636 Secretory Rate The amount of a substance secreted by cells or by a specific organ or organism over a given period of time; usually applies to those substances which are formed by glandular tissues and are released by them into biological fluids, e.g., secretory rate of corticosteroids by the adrenal cortex, secretory rate of gastric acid by the gastric mucosa. Rate, Secretory,Rates, Secretory,Secretory Rates

Related Publications

J J Legros, and D Moray, and A Fassotte, and P Franchimont
January 1983, Nephron,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
August 1978, Nihon rinsho. Japanese journal of clinical medicine,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
June 1969, The Medical journal of Australia,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
March 2005, Indian pediatrics,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
May 1988, Klinische Wochenschrift,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
January 2000, Folia medica,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
December 1962, Acta medica et biologica,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
January 1981, Acta medica Scandinavica. Supplementum,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
October 1976, Mayo Clinic proceedings,
J J Legros, and D Moray, and A Fassotte, and P Franchimont
December 1984, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!